key: cord-0889142-n2m2nyta
authors: Otmani, Hicham El; Moutawakil, Bouchra El; Rafai, Mohamed-Abdoh; Benna, Naima El; Kettani, Chafik El; Soussi, Maha; Mdaghri, Naima El; Barrou, Houcine; Afif, Hicham
title: Covid-19 and Guillain-Barré syndrome: More than a coincidence!
date: 2020-04-24
journal: Rev Neurol (Paris)
DOI: 10.1016/j.neurol.2020.04.007
sha: 74cbdf73d595f00bc7b2127f3daaa47ec6e2a0cc
doc_id: 889142
cord_uid: n2m2nyta

nan

A 70-year-old woman, receiving 7.5 mg prednisone as a maintenance therapy for rheumatoid arthritis (RA), presented with a rapidly, bilateral weakness and tingling sensation in all four extremities resulting in a total functional disability within 48 hours. The patient denied any sphincter disturbances, dyspnea or swallowing difficulties. She first received a diagnosis of RA exacerbation but no improvement was seen after corticosteroids increase. At admission to our Neurology department, at the tenth day of symptom's onset (April 13), neurological examination showed quadriplegia, hypotonia, areflexia and bilateral positive Lasègue sign. Cranial nerves were intact. Temperature, lung and cardiac auscultation were, also normal. On April 1st, three days prior to the ongoing symptom's onset, the patient presented an episode of dry cough without dyspnea or fever, spontaneously resolving within 48 hours. Initial blood tests showed no abnormality, except for a lymphocytopenia (520/ml, normal: 1500-5000). with normal white blood cell count. Chest CT (day 10) revealed ground-glass opacities in the left lung (Figure 1 ). SARS-CoV-2 on RT-PCR assay was positive at oropharyngeal swab (day 10), negative in CSF. The patient was treated with intravenous immunoglobulin (2g/kg for 5 days) and a combination of Hydroxychloroquine (600mg per day) and

Azithromycine (500 mg at the first day, then 250mg per day). No significant neurological improvement is seen after one week of treatment.

The Covid-19 infection hides many secrets that are yet to be revealed and little is known about its neurological manifestations. Here, we describe a case of a patient with mild respiratory symptoms linked to a COVID-19 infection, followed by a rapidly evolving quadriplegia arguing for a SARS-Cov-2-induced GBS. A negative PCR analysis in the CSF supports a post infectious, dysimmune mechanism.

Zhao et al. [1] reported the case of a 61-year-old man who presented with an Acute Inflammatory Demyelinating Polyneuropathy (AIDP) subtype of GBS, associated with SARS-Cov-2 infection. Being the first reported case, the authors questioned the causeeffect relationship between both events, since respiratory symptoms appeared after GBS's onset. After this first case, we found three other reports published to date. Camdessanche et al. [2] described a case of AIDP GBS subtype in a 64-year-old man, while the case of Sedaghat and Karim [3] resembled ours, an AMSAN form. Toscano et al. [4] reported a series of five patients from three Italian hospitals. Their findings were consistent with an axonal variant in three patients and with demyelinating process in two patients.

We add to the literature another case of GBS related to a Covid-19 infection. All these cases argues that SARS-Cov-2 virus could be a triggering factor of GBS. Since mild

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol

COVID-19 may induce Guillain-Barré syndrome

Guillain Barre syndrome associated with COVID-19 infection: A case report

Guillain-Barré Syndrome Associated with SARS-CoV-2

Figure 1: Chest computer tomography revealed a ground-glass opacities in the upper lobe of the left lung

The authors would like to give a special thanks to the colleagues and nurses at the departments of Neurology and Anesthesiology/reanimation and to Dr Mounir Zoubi.